Navigation Links
Estrogen therapy increases benign breast disease risk
Date:4/8/2008

Women who took conjugated equine estrogen, a commonly prescribed form of estrogen, had more than twice the risk of developing specific types of benign breast disease as women who took a placebo, according to a randomized controlled trial published online April 8 in the Journal of the National Cancer Institute.

The impact of conjugated equine estrogen on the risk of developing benign proliferative breast disease, a condition that is associated with increased risk of breast cancer, has been unclear. Some studies have reported an association while others have not. In the Women's Health Initiative study, 10,739 postmenopausal women with hysterectomy were assigned to either conjugated equine estrogen or a placebo. Previous analyses did not show an increase in breast cancer incidence in the women who took estrogen alone after a median follow-up of seven years.

To determine whether the hormone increases the risk of benign proliferative breast disease, Tom Rohan, M.D., Ph.D., of the Albert Einstein College of Medicine in New York and colleagues identified and examined non-cancerous breast biopsies in each of the Women's Health Initiative trial arms.

A total of 232 cases of benign proliferative breast disease were identified, with 155 cases among the women who took estrogen supplements and 77 in the placebo group. The risk of developing benign disease increased by more than two-fold for women taking conjugated equine estrogen, compared with those taking a placebo.

“The prevailing hypothesis concerning the natural history of breast cancer is that benign proliferative breast disease without atypia, proliferative disease with atypia, and in situ cancer represent successive steps preceding the development of invasive breast [cancer]. In keeping with this hypothesis, women with benign proliferative breast disease have an increased risk of subsequent breast cancer,” the authors write.

Although the women taking conjugated equine estrogen have not yet shown a significant increased risk of breast cancer in the Women's Health Initiative study, if this hypothesis holds true, they might show increased risk later. Ongoing follow up of the study participants may help to resolve this issue.


'/>"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. New link between estrogen and breast cancer
2. UCLA study identifies designer estrogen as potential MS drug
3. Cholesterol byproduct blocks heart health benefits of estrogen
4. Gene May Influence Breast Cancer-Estrogen Link
5. Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting
6. Estrogen Levels in Blood Predict Breast Cancers Return
7. Mitochondria play role in pathogenesis of AD and estrogen-induced neuroprotection
8. New study finds adverse effects of estrogen replacement therapy are related to the dose
9. Estrogen Supplements May Raise Odds of Benign Breast Disease
10. Vision restoration therapy shown to improve brain activity in brain injured patients
11. HIV therapy in pregnancy-data support WHO recommendations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... 23, 2017 , ... Loyale Healthcare today announced ... Smith joins other recent high-profile hires including Frank Massi, Chief Revenue Officer and ... 1993, helping physician practices and hospitals automate their clinical and financial processes to ...
(Date:8/23/2017)... ... 2017 , ... Earlier this month, the Workgroup for Electronic Data Interchange ... create efficiencies in healthcare information exchange and a trusted advisor to the U.S. Department ... featured keynote addresses by Donald W. Rucker, MD, head of the Office of the ...
(Date:8/23/2017)... ... August 23, 2017 , ... CEFEX, the Centre for Fiduciary ... standards representing best practices in the retirement plan industry. The independent CEFEX Investment ... to verify that NFP’s retirement division focuses on putting clients’ interests first and ...
(Date:8/23/2017)... , ... August 23, 2017 , ... Nightingale College continues ... Give Back Day is a time Nightingale College dedicates to serving and volunteering for ... thrive on donations and volunteers or those that need a little extra help. ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... traveling medical professionals, recently launched a new website, http://www.cirrusmedicalstaffing.com . The new ... respond to the needs of healthcare professionals who are traveling on short-term assignments ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
(Date:7/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results for ... updated its financial outlook for fiscal 2017. ... quarter, Hill-Rom reported earnings of $0.09 per diluted share ... period. These results reflect after-tax special items, including a ... the non-cash write-down of assets associated with the planned ...
Breaking Medicine Technology: